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(P.3883). Out of the 167 bypasses, 141 had foot tissue
loss. In the CPA group 93% of tissue loss with DAR healed
(median time-to-healing; 56 days) compared to 100% in
the non-DAR (98 days). Similarly in the IPA group 95%
with DAR healed (106 days) compared to 90% in the
non-DAR (94 days). While in the NPA group only 75%
with DAR healed (81 days) compared to 73% in the non-
DAR (148 days). There was only statistical significant dif-
ference in the time-to-healing between CPA/IPA versus
NPA group (P.0141).
Conclusions: The quality of the pedal arch did not
influence the patency or the amputation-free survival rates.
However, the healing and time-to-healing rates were di-
rectly influenced by the quality of the pedal arch rather than
the angiosome revascularized.
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Video Presentation
Ultrasound for the Diagnosis and Treatment of Popli-
teal Entrapment Syndrome
Marlin W. Causey, Thomas Curry, Reagan Quan, Charles
Andersen, Niten Singh.Madigan ArmyMedical Center, Ft.
Lewis, WA
Background: Popliteal Entrapment Syndrome is a rare
cause of claudication in the young population. These pa-
tients are typically referred to multiple specialists prior to
their diagnosis and optimal treatment. Ultrasound has
commonly been used as an adjunct to clinical diagnosis in
most outpatient clinics. We describe additional techniques
of using intravascular ultrasound for diagnosis when an-
giography is performed.More importantly, this video high-
lights the intraoperative use of ultrasound to ensure an
adequate and optimal myectomy when treating popliteal
entrapment syndrome as well as an ability to survey the
arterial wall for intimal injury with B mode duplex.
Technical Description: Patients are most commonly
diagnosed clinically with popliteal entrapment syndrome.
During the time of angiography, intravascular ultrasound is
able to demonstrated distinct compression of the popliteal
artery with active plantar flexion. Palpation has traditionally
been used to assess the adequacy of resection for popliteal
entrapment but this may prove to be inadequate with some
patients and intraoperative ultrasound allows assessment of
the adequacy of resection. We also perform B mode duplex
after complete resection to survey for intimal changes that
may not have been seen during the preoperative workup.
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Infrapopliteal Angioplasty for Critical Limb Ischemia:
Results at 5-year Follow-up
Ruby C. Lo, Rodney P. Bensley, Kristina A. Giles, Jeremy
D. Darling, MarkWyers, Allen D. Hamdan, Elliot Chaikof,
Marc L. Schermerhorn. Beth Israel Deaconess Medical
Center, Boston, MA
Objectives: Infrapopliteal angioplasty (PTA) is rou-
tinely used to treat critical limb ischemia (CLI) despite
limited data on long-term outcomes.
Methods: We reviewed all patients undergoing infr-
apopliteal PTA for CLI from 2004 to 2011 stratified by
TASC class. Outcomes included restenosis, primary pa-
tency, reintervention (w/ PTA or bypass), amputation,
complications, and survival.
Results: Infrapopliteal PTA (stenting 14%, multilevel
intervention 50%) was performed in 447 limbs of 401
patients (59% male) with technical success of 95% and
perioperative complications in 11%. TASC composition
was 17% A, 22% B, 29% C, and 35% D. All technical failures
involved TASC D lesions. Mean follow-up was 15 months.
5-year survival was 46%. One- and 5-year primary patency
was 55% & 36% and limb salvage was 84% & 81%. Reste-
nosis was associated with TASC C (HR 2.1, 95%CI 1.1-
3.8, P.021) and TASC D (HR 2.1, 95%CI 1.0-4.0,
P.036) lesions. Amputation rates were higher in patients
who were not candidates for bypass (HR 4.3, 95%CI 2.5-
7.3, P.001) and with TASC D lesions (HR 3.7, 95%CI
1.1-12.4, P.032). Together, freedom from restenosis,
revascularization or amputation was predicted by bypass
non-candidacy (HR 1.6, 95%CI 1.1-2.4, P.007) and
TASC C (HR 1.8, 95%CI 1.1-3.0, P.024) and TASC D
(HR 2.0, 95%CI 1.2-3.3, P.011) lesions but not multi-
level intervention (HR .9, 95%CI 0.6-1.2, P.462).
Conclusions: Infrapopliteal PTA is effective primary
therapy for TASC A and B lesions. Multilevel intervention
does adversely affect outcome.
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Patient Centered Outcomes Following Endovascular
Intervention for Critical Limb Ischemia
Javier E. Anaya-Ayala, Christopher J. Smolock, Charudatta
S. Bavare, Mitul S. Patel, Hosam F. El-Sayed, Jean Bis-
muth, Eric K. Peden, Alan Lumsden, Mark G. Davies.
Cardiovascular Surgery, Methodist DeBakey Heart & Vas-
cular Center, Houston, TX
Objectives: Over the last decade, there has been a signif-
icant increase in primary endoluminal therapy for critical limb
ischemia (CLI; rest pain and tissue loss) of the lower extremity
(LE) with limited reporting on patient centered outcomes
using the new objective performance goals of the SVS.
Methods: A prospective database of patients undergo-
ing endovascular treatment of the LE for CLI between
2000 and 2011 was queried. Patient centered outcomes of
clinical efficacy (CE; absence of recurrent symptoms, main-
tenance of ambulation and absence of major amputation),
amputation-free survival (AFS; survival without major am-
putation) and freedom from major adverse limb events
(MALE; Above ankle amputation of the index limb or
major re-intervention (new bypass graft, jump/interposi-
tion graft revision) were evaluated.
Results: 728 patients (60% male, age 6814years)
underwent LE interventions for CLI (66% tissue loss). 39%
had both SFA and tibial interventions. 71% had diabetes
mellitus, 64% had hyperlipidemia and 37% had chronic
renal insufficiency. Technical success was 96%. Overall
MACE was 3% and MALE was 22% at 30 days. At 5 years,
CE was 425%, (MeanSEM), AFS 417% and MALE
514%. CE was significantly different in those presenting
with rest pain and tissue loss (Fig).
Conclusions: Endoluminal therapy for CLI is associ-
ated with an early lowMACE but a high MALE. Longer-
term outcomes remain relatively poor with less that a
40% success in patient centered outcomes at 5 years.
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A Novel Mouse Model of Hind Limb Ischemia to Test
Therapeutic Angiogenesis
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terbury, CT
Objectives:Clinical trials currently evaluating stem cell
therapy for patients with critical limb ischemia are con-
ducted with different protocols, including use of different
stem cell populations and different injection protocols,
providing little means to compare trials and guide therapy.
Accordingly, we developed a murine model of severe isch-
emia to allow methodical testing of relevant clinical
parameters.
Methods: High femoral artery ligation and total exci-
sion of the superficial femoral artery was performed on
C57BL/6 mice. MNC were isolated from the bone mar-
row of donor mice and injected into the semimembranosus
or gastrocnemius muscle. Vascular and functional out-
comes were measured using invasive Doppler, laser Dopp-
ler perfusion imaging, and the Tarlov and ischemia scores.
Histological analysis included quantification of muscle fiber
area and number as well as capillary density.
Results: Blood flow and functional outcomes were
improved in MNC-treated mice as compared to controls
over a 4-week time course (Flow: P  .0001; Tarlov: P 
.0004; ischemia score: P .0002). MNC-treated mice also
showed greater gastrocnemius fiber area (P  .0053) and
increased capillary density (P  .0004). Dose-response
analysis showed increased angiogenesis and gastrocnemius
fiber area but no changes in macroscopic vascular flow or
functional scores. Mice injected proximally to the ischemic
area had overall similar functional outcomes to mice in-Fig.
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